BridgeBio Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Pharma (BBIO).

Price Target Range — 9 Quarters

Analyst Consensus — 25 Analysts

23Buy

2Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$94Upside to Avg. PT+32.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$97→$87
Oct 19, 2026	Citigroup	Eric Joseph	PT Cut	Neutral	$94→$91
Oct 19, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$115→$120
Oct 15, 2026	UBS	Joon Lee	Assumes	Buy	$82→$92
Oct 7, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$157→$156
Sep 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
Sep 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
Sep 1, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$96→$110
Aug 12, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$102→$107
Aug 12, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$104→$106
Aug 12, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$100→$111
Aug 11, 2026	B of A Securities	Geoff Meacham	PT Raise	Buy	$101→$104
Aug 11, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$95→$110
Aug 11, 2026	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$98→$97
Aug 11, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$111→$115
Aug 11, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$98→$102
Jul 16, 2026	Citigroup	Eric Joseph	PT Raise	Neutral	$82→$93
Jul 13, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$110→$120
Jun 16, 2026	Mizuho	Salim Syed	PT Cut	Outperform	$106→$96
Jun 3, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$104

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and lowers the price target from $94 to $91.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.

Benzinga Newsdesk

BridgeBio Pharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

BridgeBio Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PRO
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

People Also Watch

People Also Watch

BridgeBio Pharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

BridgeBio Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PROCitigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PROPiper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PROBarclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PROHC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PROHC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PRO
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target